Medtronic PLC vs Health Care Select Sector SPDR Fund — how do they compare? Medtronic PLC trades at $82.52 (market cap $106.61B), while Health Care Select Sector SPDR Fund trades at $159.49. The key difference: Medtronic PLC pays a 3.46% dividend while Health Care Select Sector SPDR Fund pays none, and Health Care Select Sector SPDR Fund is trading nearer its 52-week high, Medtronic PLC nearer its low. Which is the better fit depends on your goals.
| MDT | XLV | |
|---|---|---|
Market Cap | $106.61B | — |
Sector | Health | — |
52-Week High | $105.35 | $164.48 |
52-Week Low | $73.75 | $129.01 |
Enterprise Value | $125.36B | — |
Dividend Yield | 3.46% | — |
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $83.54, up 0.41% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $33.54B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent acquisitions, including SPR and Scientia Vascular, expand its pain therapy and neurovascular portfolios. Valuation ratios show a P/E of 22.31 and P/S of 2.95, with a consensus price target of $97.50 implying significant upside.
The outlook is positive, supported by robust fundamentals, analyst optimism, and strategic expansions. Key risks include rising debt levels and competitive pressures in medical technology. With no sell ratings from analysts and a dividend yield near a decade high, MDT presents a compelling long-term opportunity for growth and income investors, though macroeconomic and execution risks warrant monitoring.
XLV trades at $159.25, down 1.14% on the day, with technical indicators showing a bullish trend from moving averages but neutral oscillators. The healthcare ETF faces mixed sentiment with recent positive sector upgrades from State Street Investment Management but concerns about sector headwinds during earnings season. Support levels cluster around $158-160, while resistance sits at $163-165.
The healthcare sector offers defensive characteristics amid market volatility, with XLV providing diversified exposure. Key risks include patent cliffs for major holdings and election-year policy uncertainty. Analyst sentiment is cautiously optimistic given the sector's stability and innovation pipeline, though relative performance versus technology remains a concern.
Trailing returns across standard periods
Latest headlines on both assets
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →